You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

421 Results
Document
Oct 2024
Document
Oct 2024
Document
Nov 2024
Guidelines and Advice
Status: In-Review
ID: 7-13
Oct 2017
Drug
Other Name(s): Gleevec®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Document
Jan 2025
Guidelines and Advice
Status: Current
ID: 7-A-2022-1-17v3
Version: 3
Oct 2023
Document
Jan 2025
Document
Jan 2025

Pages